AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26850626 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of myocardial FA/TG ratio with LVEDV
Number of subjects: 50
Study 26850678 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-2450 40 mg/kg
Number of subjects: 13
Study 26850678 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-2450 37.5 mg once daily continuously
Number of subjects: 13
Study 26850678 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-2450 50 mg/day
Number of subjects: 13
Study 26850678 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-2450
Number of subjects: 13
Study 26850762 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic information with emotion induction (fear state)
Number of subjects: 0
Study 26850762 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic information with emotion induction (anger state)
Number of subjects: 0
Study 26850762 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic information with emotion induction (neutral state)
Number of subjects: 0
Study 26850762 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral information with emotion induction (fear state)
Number of subjects: 0
Study 26850762 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral information with emotion induction (anger state)
Number of subjects: 0
Study 26850762 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral information with emotion induction (neutral state)
Number of subjects: 0
Study 26851029 — intervention group
Group type: EXPERIMENTAL
Intervention: BEZ235 400 mg bid
Number of subjects: 31
Study 26851029 — intervention group
Group type: EXPERIMENTAL
Intervention: BEZ235 300 mg bid
Number of subjects: 31
Study 26851813 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held single-lead electrocardiogram (ECG) device (MyDiagnostick) used for screening during influenza vaccination.
Number of subjects: 3269
Study 26851940 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' MVPA on weekdays
Number of subjects: 199
Study 26851940 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' MVPA on weekend days
Number of subjects: 199
Study 26851940 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's MVPA on weekdays
Number of subjects: 199
Study 26851940 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's MVPA on weekend days
Number of subjects: 199
Study 26851940 — intervention group
Group type: EXPERIMENTAL
Intervention: Total counts per minute for children on weekdays
Number of subjects: 199
Study 26851940 — intervention group
Group type: EXPERIMENTAL
Intervention: Total counts per minute for children on weekend days
Number of subjects: 199
Study 26851940 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of total counts per minute on weekend days
Number of subjects: 199
Study 26851940 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of total counts per minute on weekdays
Number of subjects: 199
Study 26851940 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of parents and children for MVPA on weekend days
Number of subjects: 199
Study 26851940 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of parents and children for MVPA on weekdays
Number of subjects: 199
Study 26851940 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of sedentary time on weekend days
Number of subjects: 199
Study 26851940 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of sedentary time on weekdays
Number of subjects: 199
Study 26852132 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline treatment (specifically epirubicin)
Number of subjects: 4
Study 26852132 — intervention group
Group type: EXPERIMENTAL
Intervention: Histone deacetylase small-molecule inhibitors
Number of subjects: 4
Study 26852132 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin-resistant cells
Number of subjects: 4
Study 26852181 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier use (non-nutritive sucking)
Number of subjects: 30
Study 26852658 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor
Number of subjects: 0
Study 26853180 — intervention group
Group type: EXPERIMENTAL
Intervention: ustekinumab
Number of subjects: 2076
Study 26853249 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital care (PHC)
Number of subjects: 6123
Study 26853249 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital medication (PHM)
Number of subjects: 6123
Study 26853249 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 6123
Study 26853249 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytics
Number of subjects: 6123
Study 26853249 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from symptoms onset to ECG
Number of subjects: 6123
Study 26853249 — intervention group
Group type: EXPERIMENTAL
Intervention: First medical attention (FMA)
Number of subjects: 6123
Study 26853249 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG within 10 minutes of FMA
Number of subjects: 6123
Study 26853647 — intervention group
Group type: EXPERIMENTAL
Intervention: AIEOP-BFM protocols (2000 and 2009)
Number of subjects: 49
Study 26853647 — intervention group
Group type: EXPERIMENTAL
Intervention: AIEOP-BFM 2009 protocol
Number of subjects: 49
Study 26853647 — intervention group
Group type: COMPARATOR
Intervention: AIEOP-BFM protocols
Number of subjects: 49
Study 26854432 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging therapies targeting castration-resistant prostate cancer
Number of subjects: 0
Study 26854578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (300, 600 mg/day or flexible)
Number of subjects: 2935
Study 26854578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (all doses)
Number of subjects: 2935
Study 26854578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 2935
Study 26854578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2935
Study 26854928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequences of 2-millisecond light flashes (n = 31) with different interstimulus intervals (ISIs; ranging from 2.5 to 240 seconds)
Number of subjects: 39
Study 26854928 — intervention group
Group type: COMPARATOR
Intervention: Continuous light (n = 8)
Number of subjects: 39
Study 26855099 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% cervical effacement in spontaneous labor
Number of subjects: 3902
Study 26855099 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% cervical effacement with oxytocin
Number of subjects: 3902
Study 26855613 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (MV) for more than 48 hours
Number of subjects: 0
Study 26855613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing-sensitive outcomes (NSO)
Number of subjects: 0
Study 26855613 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU stressors
Number of subjects: 0
Study 26855613 — intervention group
Group type: EXPERIMENTAL
Intervention: Other clinical variables
Number of subjects: 0
Study 26855665 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed guar gum (PHGG) 6 g/day
Number of subjects: 108
Study 26855665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 26855682 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavoglurant (25, 50, or 100 mg BID)
Number of subjects: 134
Study 26855682 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavoglurant (100 mg BID or highest tolerated dose)
Number of subjects: 134
Study 26855682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 26856824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 5
Study 26856824 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-dialysis dolutegravir concentrations
Number of subjects: 5
Study 26856824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosage adjustments
Number of subjects: 5
Study 26857191 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphones in standby mode directly over the ICD generator
Number of subjects: 63
Study 26857191 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphones in dialing and operating modes directly over the generator casing and over the parasternal region
Number of subjects: 63
Study 26857558 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 2500
Study 26857702 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus oxaliplatin/capecitabine
Number of subjects: 51
Study 26857907 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective electrophysiologically guided atrial substrate modification after circumferential pulmonary vein isolation and cavotricuspid isthmus ablation
Number of subjects: 86
Study 26857907 — intervention group
Group type: COMPARATOR
Intervention: Stepwise approach (historical control group)
Number of subjects: 86
Study 26858124 — intervention group
Group type: EXPERIMENTAL
Intervention: CD3/CD28 costimulated umbilical cord blood T cells (10^5 cells/kg)
Number of subjects: 4
Study 26858336 — intervention group
Group type: EXPERIMENTAL
Intervention: NEOD001 (24 mg/kg)
Number of subjects: 27
Study 26858840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 26858840 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU/d of vitamin D3
Number of subjects: 328
Study 26858840 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/d of vitamin D3
Number of subjects: 328
Study 26858840 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU/d of vitamin D3
Number of subjects: 328
Study 26859094 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional protein fortification
Number of subjects: 152
Study 26859103 — intervention group
Group type: EXPERIMENTAL
Intervention: AHSCT (Autologous Hematopoietic Stem Cell Transplantation) protocol using fludarabine in an outpatient setting
Number of subjects: 16
Study 26859538 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily tiotropium 5 μg
Number of subjects: 0
Study 26859538 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily tiotropium 2.5 μg
Number of subjects: 0
Study 26859538 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both regimens
Number of subjects: 0
Study 26859538 — intervention group
Group type: EXPERIMENTAL
Intervention: Total tiotropium exposure
Number of subjects: 0
Study 26859761 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG-ATCC 53103 (LGG) treatment for 28 days
Number of subjects: 11
Study 26859761 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment (Day 56)
Number of subjects: 11
Study 26859866 — intervention group
Group type: EXPERIMENTAL
Intervention: EMR
Number of subjects: 203
Study 26860632 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab plus tandutinib
Number of subjects: 41
Study 26860741 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital games for cognitive functioning and general well-being
Number of subjects: 0
Study 26860741 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 26861157 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFAs)
Number of subjects: 73
Study 26861157 — intervention group
Group type: COMPARATOR
Intervention: Children with ADHD
Number of subjects: 73
Study 26861157 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower blood levels of PUFA
Number of subjects: 73
Study 26861458 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA TCB
Number of subjects: 110
Study 26861602 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus added to trastuzumab and paclitaxel as first-line therapy
Number of subjects: 0
Study 26861602 — intervention group
Group type: COMPARATOR
Intervention: Control group (trastuzumab and paclitaxel without everolimus)
Number of subjects: 0
Study 26861666 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib (Group D)
Number of subjects: 90
Study 26861666 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 90
Study 26861740 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (200mg qd titrated to 400mg BID) with infusional 5-FU (225 mg/m(2)/24h) and radiation (28 fractions at 1.8 Gy)
Number of subjects: 17
Study 26861867 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 2113
Study 26861867 — intervention group
Group type: COMPARATOR
Intervention: ICS ± LABA
Number of subjects: 2113
Study 26861867 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (in subjects without comorbid asthma)
Number of subjects: 2113
Study 26861867 — intervention group
Group type: COMPARATOR
Intervention: ICS ± LABA (in subjects without comorbid asthma)
Number of subjects: 2113
Study 26861905 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg daily for 2 years
Number of subjects: 37
Study 26861921 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 μg nonaqueous glucagon
Number of subjects: 12
Study 26861921 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 μg nonaqueous glucagon
Number of subjects: 12
Study 26861921 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 μg nonaqueous glucagon
Number of subjects: 12
Study 26861921 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-insulin administration with 75 μg glucagon
Number of subjects: 12
Study 26861921 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-insulin administration with 150 μg glucagon
Number of subjects: 12
Study 26861921 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-insulin administration with 300 μg glucagon
Number of subjects: 12
Study 26861943 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed clinical malaria (CCM)
Number of subjects: 1640
Study 26861943 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic parasitaemia (AP)
Number of subjects: 1640
Study 26861943 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive blood smears
Number of subjects: 1640
Study 26863635 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with histamine dihydrochloride and low-dose interleukin-2
Number of subjects: 84
Study 26863635 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of CD8+ T cells with specificity for leukemia-associated antigens
Number of subjects: 84
Study 26864153 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin (12-week duration)
Number of subjects: 129
Study 26864194 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.3 mg·kg(-1)
Number of subjects: 36
Study 26864236 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic therapy
Number of subjects: 216
Study 26864236 — intervention group
Group type: COMPARATOR
Intervention: Conventional glycemic therapy
Number of subjects: 216
Study 26864236 — intervention group
Group type: EXPERIMENTAL
Intervention: LW-1
Number of subjects: 216
Study 26864236 — intervention group
Group type: EXPERIMENTAL
Intervention: SIF and CLF
Number of subjects: 216
Study 26864236 — intervention group
Group type: EXPERIMENTAL
Intervention: SIF and LW-1
Number of subjects: 216
Study 26864236 — intervention group
Group type: EXPERIMENTAL
Intervention: LW-1 and CLF
Number of subjects: 216
Study 26864355 — intervention group
Group type: EXPERIMENTAL
Intervention: TMAO and choline concentrations at least the median (n = 83)
Number of subjects: 283
Study 26864355 — intervention group
Group type: COMPARATOR
Intervention: TMAO and choline concentrations less than the median (n = 82)
Number of subjects: 283
Study 26864355 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes presence
Number of subjects: 283
Study 26864355 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex (male)
Number of subjects: 283
Study 26864355 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex (female)
Number of subjects: 283
Study 26864355 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group analysis
Number of subjects: 283
Study 26864370 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant mean energy intake for 92.2 ± 7.9 days
Number of subjects: 13
Study 26864794 — intervention group
Group type: EXPERIMENTAL
Intervention: Strenuous exercise (amateur cycling race)
Number of subjects: 92
Study 26865277 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-92a mimics
Number of subjects: 138
Study 26865277 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-92a inhibitors
Number of subjects: 138
Study 26865277 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous miR-92a expression
Number of subjects: 138
Study 26865277 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative model predictions
Number of subjects: 138
Study 26865594 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-IM (3-dose IM priming with a single booster at 42 months)
Number of subjects: 0
Study 26865594 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-IM (3-dose IM priming with boosters at 18 and 42 months)
Number of subjects: 0
Study 26865594 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-IM (3-dose IM priming with boosters at 12, 18, 30, and 42 months)
Number of subjects: 0
Study 26865594 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-SQ (licensed priming series of 6 doses with two annual boosters administered subcutaneously)
Number of subjects: 0
Study 26865594 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-IM (licensed priming series of 6 doses with two annual boosters administered intramuscularly)
Number of subjects: 0
Study 26865594 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo control
Number of subjects: 0
Study 26865869 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole-body vibration training (6 Hz, Noise 4 SR-WBV)
Number of subjects: 9
Study 26865869 — intervention group
Group type: COMPARATOR
Intervention: Sham / 1 Hz, Noise 1 SR-WBV
Number of subjects: 9
Study 26866015 — intervention group
Group type: EXPERIMENTAL
Intervention: AFFITOPE® AD02 (amyloid-beta-targeting vaccine)
Number of subjects: 318
Study 26866015 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted ADAS-cog scale
Number of subjects: 318
Study 26866015 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted ADCS-ADL scale
Number of subjects: 318
Study 26866015 — intervention group
Group type: COMPARATOR
Intervention: Traditional scales
Number of subjects: 318
Study 26866015 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite scales
Number of subjects: 318
Study 26866579 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing (WES) results disclosure
Number of subjects: 167
Study 26866579 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncologists' experience with germ-line tests
Number of subjects: 167
Study 26866579 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' genetic knowledge
Number of subjects: 167
Study 26867033 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker models developed with combined traditional and novel biomarkers
Number of subjects: 140
Study 26867033 — intervention group
Group type: COMPARATOR
Intervention: Traditional clinical markers alone
Number of subjects: 140
Study 26867061 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral renal denervation (RDN) performed with a single electrode Symplicity catheter.
Number of subjects: 1
Study 26867073 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait anxiety in women
Number of subjects: 55
Study 26867073 — intervention group
Group type: EXPERIMENTAL
Intervention: High trait anxiety in women
Number of subjects: 55
Study 26867073 — intervention group
Group type: EXPERIMENTAL
Intervention: Low trait anxiety in women
Number of subjects: 55
Study 26867073 — intervention group
Group type: EXPERIMENTAL
Intervention: State anxiety in men
Number of subjects: 55
Study 26867206 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon-α2a ± ribavirin (ATAHC II)
Number of subjects: 82
Study 26867206 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon-α2a, ribavirin and telaprevir (DARE-C I)
Number of subjects: 82
Study 26867531 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinitis Control Scoring System (RCSS)
Number of subjects: 50
Study 26868015 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI T2 mapping
Number of subjects: 28
Study 26868015 — intervention group
Group type: EXPERIMENTAL
Intervention: dGEMRIC
Number of subjects: 28
Study 26868114 — intervention group
Group type: EXPERIMENTAL
Intervention: DAIR treatment
Number of subjects: 35
Study 26868114 — intervention group
Group type: EXPERIMENTAL
Intervention: DAIR-only
Number of subjects: 35
Study 26868433 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variation at IRS1 locus (rs4675095-T)
Number of subjects: 597
Study 26868433 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variation at ENPP1 locus (rs4897549-A)
Number of subjects: 597
Study 26868433 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variation at TRIB3 locus (rs7265169-A)
Number of subjects: 597
Study 26868433 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variation at ENPP1 locus (rs858340-G)
Number of subjects: 597
Study 26868433 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity assessment via euglycaemic insulin clamp
Number of subjects: 597
Study 26868693 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 249
Study 26868955 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear processing
Number of subjects: 0
Study 26868955 — intervention group
Group type: EXPERIMENTAL
Intervention: Semicompressive scheme
Number of subjects: 0
Study 26868955 — intervention group
Group type: COMPARATOR
Intervention: NAL-NL2 prescription rule
Number of subjects: 0
Study 26869376 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg dose of glycoconjugate GBS vaccine (serotypes Ia, Ib, and III, with CRM197) administered intramuscularly at 24-35 weeks' gestation.
Number of subjects: 270
Study 26869384 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence to the DASH diet
Number of subjects: 74404
Study 26869472 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty and self-expanding stents
Number of subjects: 100
Study 26869532 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue IgG-antibodies
Number of subjects: 162
Study 26869532 — intervention group
Group type: EXPERIMENTAL
Intervention: Chikungunya IgG-antibodies
Number of subjects: 162
Study 26869532 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue incidence
Number of subjects: 162
Study 26869532 — intervention group
Group type: EXPERIMENTAL
Intervention: Chikungunya incidence
Number of subjects: 162
Study 26869630 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplo-cord transplant
Number of subjects: 290